In this section

Clinical trials

Active clinical trials

Clinical Trials - Diseases by specialty group


Leukemia 14

    Protocol ID
  • Associated disease
    Title
    Evaluation of Long-term Safety in Paediatric Patients With B-precursor Acute Lymphoblastic Leukemia (ALL) who Have Been Treated With Either Blinatumomab or Chemotherapy, Followed by Transplantation
    International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
    A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
    COG-AALL1732
  • Acute Lymphoblastic Leukemia (ALL)
  • Other Leukemia
    A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
    IIT-MOSKOP-MABD
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Chronic Mylegenous Leukemia (CML)
  • Myeloma/Myelodysplastic Syndrome (MDS)
  • Other Leukemia
    Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation with Alpha/Beta T-Cell and B-Cell Depletion for Patients with Hematologic Malignancies with Targeted ATG Dosing Pilot Study, IDE 13641
    Communication in the Early Pediatric Cancer Treatment Period
    IIT-Steineck-CARTPLUS: Chimeric Antigen Receptor T-cell Pediatrics Living with Uncertainty (CAR T-PLUS) Intervention Proof of Concept Study
    Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3 and 4-1BB Signaling Domains in Patients with Relapsed and/or Refractory CD19 or CD20 B-Cell Acute Lymphoblastic Leukemia
    MAGIC-LRPEDS
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Other Leukemia
    Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD
    NMDP-UMCC2018-081
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Chronic Mylegenous Leukemia (CML)
  • Myeloma/Myelodysplastic Syndrome (MDS)
    A Phase 1/2 Multi-Center Trial of Vorinistat for Graft vs Host Disease Prevention in Children, Adolescents, and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
    PBMTC-ONC1401
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Myeloma/Myelodysplastic Syndrome (MDS)
    The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
    A Phase II Pilot Trial to Estimate Survival After a Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation-Sequence (NGS) Minimal Residual Disease (MRD) Negative
    A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients with Relapsed and Refractory Acute Myeloid Leukemia
    A Phase II Pilot Study of Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial)
Contact us

For more information about cancer and blood disorders clinical trials, email us or call

(414) 955-4727

Get a second opinion

It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.

Why participate in clinical trials?

Michael Burke, MD

"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD